Dr. Vij on the Optimal Induction Therapy in Multiple Myeloma

Ravi Vij, MD
Published: Friday, Oct 19, 2018



Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Transplant remains the standard of care in eligible patients, says Vij, as it is known to demonstrate a superior progression-free survival. The optimal induction regimen is unknown, explains Vij, though most physicians will use bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd).

In the frontline setting, carfilzomib (Kyprolis) is being examined as a potential substitute for bortezomib—in some cases, it is already being implemented into practice. The use of carfilzomib is being driven by studies that have demonstrated a superior depth of response compared with what has been seen historically. Physicians are eagerly awaiting the randomized study comparing frontline carfilzomib, lenalidomide, and dexamethasone with VRd, says Vij, which will help determine the optimal induction regimen.


Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the optimal induction therapy in the treatment of patients with multiple myeloma.

Transplant remains the standard of care in eligible patients, says Vij, as it is known to demonstrate a superior progression-free survival. The optimal induction regimen is unknown, explains Vij, though most physicians will use bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd).

In the frontline setting, carfilzomib (Kyprolis) is being examined as a potential substitute for bortezomib—in some cases, it is already being implemented into practice. The use of carfilzomib is being driven by studies that have demonstrated a superior depth of response compared with what has been seen historically. Physicians are eagerly awaiting the randomized study comparing frontline carfilzomib, lenalidomide, and dexamethasone with VRd, says Vij, which will help determine the optimal induction regimen.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x